To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
AstraZeneca Licenses Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Read time: Less than a minute
AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
